APACHE III

Acute Physiology & Chronic Health Evaluation III. A ‘third-generation’ system for estimating the risk of hospital death in adult ICU patients based on physiologic assessments of most severely affected values during the first 24 hours in the ICU and subjecting the results to logistic regression modelling techniques

APACHE III

Acute Physiology & Chronic Health Evaluation Intensive care A 'third-generation' system for estimating the risk of hospital death in adult ICU Pts based on physiological assessments of most severely affected values during the first 24 hrs in the ICU and subjecting the results to logistic regression modeling techniques. See Medisgroups, Prognostic scoring systems.
References in periodicals archive ?
Of 246 admissions, median NICU stay was 4 (1, 61) days; APACHE III score was 56 (16, 145).
To examine the association between APACHE III and SOFA scores and midazolam dose, we used scatter plots and linear regression.
Statistical analysis: Risk factors [age, gender, APACHE III score and Multiple Organ Dysfunction Score (MODS) at the admission day, TBSA, the mean length of hospital stay, the mean admission days, operation time, the mean white blood cells (WBC), co-morbidities, transfer from other hospital, invasive device usage and prior broad spectrum antibiotic usage] for NIs were determined using Chi square test and univariate analysis.
Because of the lack of available data to calculate a standard APACHE III score for non-ICU patients, we modified the APACHE III score by excluding variables that were unavailable for non-ICU patients.
There were no statistically significant differences in age, gender, ethnicity, and severity of illness measured by APACHE III prognostic model between the NRT and control groups.
The risk of developing CIPNM for ventilated patients can be assessed based on the presence of SIRS and APACHE III scoring.
They also had higher APACHE III scores, which indicated that they were more severely ill, and more comorbidities compared with both control groups.
The authors retrospectively recorded measurement of illness acuity through calculation of APACHE III and their own "Bleeding" score, and calculated the underlying burden of chronic illness through the previously validated Charlson Comorbidity index.
Additionally, capital has been used to develop and disseminate software without which there would be little or no practical use of the APACHE III methodology.
APACHE III, with more homogeneous disease categories and risk estimates developed from a nationally representative database, is under development.
The two groups were analyzed in terms of age, BMI, SOFA, APACHE III, and ISS scores (three well-established severity of illness grading scales) with no statistically significant differences detected across these variables.